Hye Won Kim

Hye Won Kim

Auto-generated profile, based on publicly available information

Hye Won Kim

Division of Biostatistics, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2026 in International Journal of Thyroidology
Verified
Journal Article
Open access
PDF file
SKSeok-Kyung Kang
Seok-Kyung Kang
MRMiri Ryu
Miri Ryu
MLMeehyun Lee
Meehyun Lee
HKHye Won Kim
Hye Won Kim
HHHanpyo Hong
Hanpyo Hong
SLSeungju Lee
Seungju Lee
Seok-Kyung Kang, Miri Ryu, Meehyun Lee, Hye Won Kim, Han Pyo Hong and Seungju Lee. Int J Thyroidol 2026;19:78-84. https://doi.org/10.11106/ijt.2026.19.1.78

12 November 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YLYoung Tae Lim
Young Tae Lim
HHHanpyo Hong
Hanpyo Hong
HKHyewon Kim
Hyewon Kim
JLJae Min Lee
Jae Min Lee
YJYoungjin Jung
Youngjin Jung
Background/Objectives: Younger age is an established risk factor for coronary artery abnormalities (CAAs) in Kawasaki disease (KD), but nationwide data on age-related differences in treatment and antithrombotic management are limited. We characterized age-specific patterns of claims-coded CAAs, initial treatment, and antithrombotic prescribing in Korean children with KD. Methods: Using the Health Insurance Review and Assessment Service database, we analyzed 52,247 patients with KD diagnosed in 2010–2023, stratified by age (<1, 1 to <5, and 5 to <18 years). CAAs were identified by diagnostic code I25.4, which does not distinguish aneurysm from ectasia. Factors associated with claims-coded CAAs were explored using multivariable logistic regression. Results: Claims-coded CAAs were identified in 3.3% of patients, with similar proportions across age groups (3.5%, 3.1%, and 3.5%; p = 0.069). Older children (≥5 years) more frequently received initial intravenous immunoglobulin (IVIG) plus corticosteroid therapy (24.3% vs. 16.0–18.5%; p < 0.001). Among patients with claims-coded CAAs, older children more often had cumulative, not necessarily concurrent, exposure to aspirin, clopidogrel, and warfarin during follow-up (10.8% vs. 3.7–6.2%) and antithrombotic prescriptions for >12 months (40.6% vs. 25.3–25.6%). IVIG prescription on hospital Day ≥ 3 was associated with higher odds of claims-coded CAAs (adjusted odds ratio, 1.48; 95% confidence interval, 1.22–1.80). Conclusions: Although the proportion of claims-coded CAAs was similar across age groups, recorded antithrombotic prescribing among affected children differed by age; because observation time was not standardized, whether this reflects true management differences or lesion severity requires validation. KD should remain in the differential diagnosis for school-age children.